知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

1982 records (took 0.066 seconds)

    COMPOSITIONS AND METHODS TO TREAT AIDS
    82.
    发明申请
    COMPOSITIONS AND METHODS TO TREAT AIDS 有权
    组合物和治疗艾滋病的方法

    公开(公告)号：US20160015802A1

    公开(公告)日：2016-01-21

    申请号：US14776682

    申请日：2014-03-13

    Applicant: University of Massachusetts

    Inventor： Shan Lu ,  Shixia Wang

    IPC: A61K39/21 ,  C12N7/00 ,  A61K45/06 ,  C07K14/005

    CPC classification number: A61K39/21 ,  A61K39/12 ,  A61K45/06 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/575 ,  A61K2039/70 ,  C07K14/005 ,  C12N7/00 ,  C12N2740/16134

    Abstract: Polyvalent, primary isolate nucleic acid compositions for inducing an immune response against HIV are disclosed. The compositions and methods described herein are for the use of a nucleic acid composition that encodes one or more different HIV envelope glycoproteins. The synthetic, codon-optimized DNAs encoding one or more HIV proteins are a combination of different nucleic acids, such as DNA plasmids, generated from primary isolate DNA of different HIV major group genetic clades and/or different proteins. HIV polypeptide compositions for inducing an immune response against HIV are also disclosed. Methods for using the polypeptide compositions before, at the same time as, and/or after administration of the DNA compositions are provided.

    Abstract translation: 公开了用于诱导针对HIV的免疫应答的多价的初级分离核酸组合物。 本文描述的组合物和方法是用于编码一种或多种不同HIV包膜糖蛋白的核酸组合物。 编码一种或多种HIV蛋白质的合成的密码子优化的DNA是由不同的HIV主要群体遗传进化枝和/或不同蛋白质的初级分离物DNA产生的不同核酸，例如DNA质粒的组合。 还公开了用于诱导针对HIV的免疫应答的HIV多肽组合物。 提供了在给予DNA组合物之前，同时和/或之后使用多肽组合物的方法。

    CYTOMEGALOVIRUS VECTORS ENABLING CONTROL OF T CELL TARGETING
    84.
    发明申请
    CYTOMEGALOVIRUS VECTORS ENABLING CONTROL OF T CELL TARGETING 有权
    CYCEGEGALOVIRUS矢量控制T细胞靶向

    公开(公告)号：US20160010112A1

    公开(公告)日：2016-01-14

    申请号：US14773130

    申请日：2014-03-05

    Applicant: OREGON HEALTH & SCIENCE UNIVERSITY

    Inventor： Louis Picker ,  Scott Hansen ,  Klaus Frueh ,  Daniel Malouli

    IPC: C12N15/86 ,  A61K39/04 ,  C12N7/00 ,  A61K39/21

    CPC classification number: C12N15/86 ,  A61K39/04 ,  A61K39/12 ,  A61K39/21 ,  A61K48/00 ,  A61K2039/5256 ,  A61K2039/572 ,  C12N7/00 ,  C12N2710/16011 ,  C12N2710/16143 ,  C12N2740/15034

    Abstract: Disclosed herein are CMV vectors that include a heterologous protein antigen, an active UL131 protein (or an ortholog thereof), an active UL128 protein (or an ortholog thereof), but wherein the CMV vector lacks an active UL130 protein (or an ortholog thereof). Also disclosed herein are CMV vectors comprising: a heterologous protein antigen, an active UL131 protein (or an ortholog thereof), an active UL130 protein (or an ortholog thereof), but wherein the CMV vector lacks an active UL128 protein. Further disclosed are methods of using CMV vectors to generate an immune response characterized as having at least 10% of the CD8+ T cells directed against epitopes presented by MHC Class II.

    Abstract translation: 本文公开了包含异源蛋白质抗原，活性UL131蛋白（或其直系同源物），活性UL128蛋白（或其直系同源物），但其中CMV载体缺少活性UL130蛋白（或其直系同源物）的CMV载体， 。 本文还公开了包含：异源蛋白抗原，活性UL131蛋白（或其直系同源物），活性UL130蛋白（或其直系同源物），但其中CMV载体缺少活性UL128蛋白的CMV载体。 进一步公开的是使用CMV载体产生特征为具有至少10％的CD8 + T细胞针对MHC II类呈递的表位的免疫应答的方法。

    VACCINE FORMULATION
    90.
    发明申请
    VACCINE FORMULATION 审中-公开
    疫苗配方

    公开(公告)号：US20150359874A1

    公开(公告)日：2015-12-17

    申请号：US14382711

    申请日：2013-03-05

    Applicant: DUKE UNIVERSITY

    Inventor： Anthony M. Moody ,  Barton F. Haynes

    IPC: A61K39/21 ,  C12N7/00

    CPC classification number: A61K39/21 ,  A61K31/01 ,  A61K39/12 ,  A61K2039/55511 ,  A61K2039/55516 ,  A61K2039/55561 ,  A61K2039/55566 ,  A61K2039/55572 ,  C12N7/00 ,  C12N2740/16134

    Abstract: The present invention relates, in general, to a method of inducing an immune response to HIV-1 in a mammal and, in particular, to a vaccine formulation suitable for use in such a method comprising an HIV-1 envelope (Env) immunogen comprising recombinant Envs with some degree of high-mannose glycan residues and a Toll-like receptor (TLR) agonist-supplemented squalene-based adjuvant.

    Abstract translation: 本发明一般涉及在哺乳动物中诱导对HIV-1的免疫应答的方法，特别涉及适用于包含HIV-1包膜（Env）免疫原的疫苗制剂的方法，所述HIV-1包膜（Env）免疫原包含 具有一定程度的高甘露糖聚糖残基的重组Env和基于Toll样受体（TLR）激动剂补充的基于角鲨烯的佐剂。

Patent Agency Ranking